Endostatin inhibits adhesion of endothelial cells to collagen I via alpha(2)beta(1) integrin, a possible cause of prevention of chondrosarcoma growth.
Endostatin derived from collagen XVIII is a potent endogenous anti-angiogenic factor that induces regression of various tumors of epithelial origin. Endostatin has been shown to inhibit endothelial cell functions, however, its effect remains controversial. We first attempted here to apply the inhibitory effect of recombinant human endostatin on chondrosarcomas, which originate from the mesenchyme, in nude mice. Endostatin induced reduction of chondrosarcoma growth and tumor angiogenesis in vivo. However, endostatin showed no effect on the proliferation and migration of chondrosarcoma cells in vitro. Next, we investigated the interactions between endostatin and endothelial cells in detail. Endostatin inhibited the migration on and attachment to collagen I but did not affect the proliferation of endothelial cells. Although the migration of endothelial cells was stimulated by angiogenic factors such as basic fibroblast growth factor and vascular endothelial growth factor, endostatin showed similar inhibitory effects on it in the presence and absence of the stimulants. Moreover, the inhibitory effect against endothelial cell attachment to collagen I was attenuated or modulated in the presence of neutralizing antibodies of alpha(2), alpha(5)beta(1), and alpha(V)beta(3) integrins but not that of alpha(1) integrin. Our results suggest that endostatin might suppress the alpha(2)beta(1) integrin function of endothelial cells via alpha(5)beta(1) or alpha(V)beta(3) integrin. We propose here that endostatin might be effective for anti-angiogenic therapy for human chondrosarcomas through the suppression of alpha(2)beta(1) integrin functions in endothelial cells.
Furumatsu
Takayuki
T
Department of Molecular Biology and Biochemistry, Okayama University Graduate School of Medicine and Dentistry, 700-8558, Japan.
Yamaguchi
Noriko
N
Nishida
Keiichiro
K
Kawai
Akira
A
Kunisada
Toshiyuki
T
Namba
Masayoshi
M
Inoue
Hajime
H
Ninomiya
Yoshifumi
Y
D000818:Animals; D001859:Bone Neoplasms / Q000628:therapy; D002448:Cell Adhesion; D002455:Cell Division; D002460:Cell Line; D002465:Cell Movement; D002478:Cells, Cultured; D002813:Chondrosarcoma / Q000378:metabolism* / Q000628:therapy; D003094:Collagen / Q000378:metabolism* / Q000502:physiology; D024042:Collagen Type I / Q000378:metabolism*; D043170:Collagen Type XVIII; D043169:Endostatins; D016228:Endothelial Growth Factors / Q000378:metabolism; D004730:Endothelium, Vascular / Q000166:cytology*; D016222:Fibroblast Growth Factor 2 / Q000378:metabolism; D006801:Humans; D007074:Immunoglobulin G / Q000378:metabolism; D007150:Immunohistochemistry; D016023:Integrins / Q000378:metabolism*; D008222:Lymphokines / Q000378:metabolism; D051379:Mice; D008819:Mice, Nude; D009389:Neovascularization, Pathologic; D010446:Peptide Fragments / Q000378:metabolism* / Q000502:physiology; D038981:Receptors, Collagen; D013997:Time Factors; D014407:Tumor Cells, Cultured; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
D024042:Collagen Type I; D043170:Collagen Type XVIII; D043169:Endostatins; D016228:Endothelial Growth Factors; D007074:Immunoglobulin G; D016023:Integrins; D008222:Lymphokines; D010446:Peptide Fragments; D038981:Receptors, Collagen; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D016222:Fibroblast Growth Factor 2; D003094:Collagen